By [Journalist Name/Agency]
The landscape of metastatic breast cancer (MBC) research and advocacy is witnessing a transformative moment as METAvivor, a leading non-profit organization dedicated to the terminal stage of the disease, announces its 2025 grant cycle allocations. In a poignant update from the organization’s president, Dr. Kelly Shanahan, the group revealed a commitment of $3.55 million across 14 new research grants, pushing their total historical funding toward the $41 million mark. This milestone, however, comes set against the sobering reality of the disease itself, as Dr. Shanahan shared news of her own cancer progression and the logistical hurdles of seeking life-extending clinical trials.
Main Facts: A Grassroots Powerhouse Hits the $41 Million Milestone
METAvivor’s 2025 grant cycle represents a significant injection of capital into a field that has historically been underfunded. While breast cancer awareness is a global phenomenon, metastatic breast cancer—Stage IV cancer that has spread beyond the breast to vital organs—receives only a fraction of total research funding, despite being the cause of nearly all breast cancer deaths.
The $3.55 million allocated for 2025 will support 14 distinct research projects. These grants are specifically designed to move the needle on treatments that can extend the lives of those living with MBC or, ideally, lead to a cure. This latest round brings the organization’s cumulative total to approximately 230 grants awarded since 2020, totaling nearly $41 million.
What distinguishes METAvivor from larger, more corporate non-profits is its operational structure. The organization remains a grassroots entity governed by a volunteer board. Most of these board members, including Dr. Shanahan, are themselves living with MBC. This "patient-led" model ensures that every dollar raised is directed toward research that prioritizes the needs of those in the metastatic community, rather than early-stage prevention or awareness campaigns that do not address the needs of the terminally ill.
Chronology: The Evolution of METAvivor and the 2025 Cycle
The trajectory of METAvivor’s influence has seen a steep incline over the last half-decade. To understand the significance of the 2025 announcement, one must look at the timeline of the organization’s growth and the current grant timeline.
- 2009–2019: The Formative Years: METAvivor was founded by patients who were frustrated by the lack of research dedicated to Stage IV disease. For the first decade, the organization focused on building a donor base and establishing the "100% to research" promise, where all public donations go directly to scientific grants.
- 2020: The Acceleration Phase: The first major wave of modern grants was awarded, establishing a rigorous peer-review process involving both scientific experts and patient advocates.
- Late 2023 – Early 2024: The 2025 Grant Review: The 14 grants announced this month are the result of a year-long process. Scientists from across the globe submitted proposals which were then vetted for scientific merit and potential impact on patient longevity.
- September 2024: The Current Announcement: Dr. Kelly Shanahan’s "Letter from the President" serves as the official transition into the 2025 cycle, signaling the release of funds and the introduction of new leadership members.
- Looking Ahead to 2025: The official awardees will be announced in the coming weeks, and the "Groundswell" advocacy event will take place, allowing patients to lobby for legislative changes from their homes.
Supporting Data: The Economics of MBC Research
The financial data surrounding METAvivor’s growth highlights a shift in how niche medical research is funded. The $41 million raised since 2020 is particularly impressive when considering the organization’s low overhead.
Funding Breakdown:
- 2025 Cycle Total: $3,550,000
- Number of Grants: 14
- Average Grant Size: Approximately $253,571
- Cumulative Impact: ~230 grants since 2020
The necessity of this funding is underscored by the current state of MBC clinical trials. Currently, only about 7% of all breast cancer research funding is dedicated to the metastatic stage. METAvivor’s contribution acts as a critical bridge for researchers who may not qualify for larger federal grants (such as those from the NIH) without the preliminary data that METAvivor grants help generate.
Furthermore, the data regarding patient travel for clinical trials—as highlighted by Dr. Shanahan’s move from California to Tennessee—reflects a significant "geographic burden" in oncology. Studies show that travel distance is a major barrier to trial enrollment, often excluding patients from lower socioeconomic backgrounds. Dr. Shanahan’s personal journey highlights that even for a physician-patient, the logistics of MBC care are arduous.
Official Responses: Leadership Transition and Advocacy Initiatives
In her official capacity, Dr. Shanahan emphasized that the organization is entering a phase of "optimized engagement." The introduction of new board members is intended to bring fresh perspectives to the grassroots model. These members are tasked with overseeing "Groundswell," the organization’s signature advocacy program.
Groundswell is a digital-first initiative designed to accommodate the physical limitations of many MBC patients. By allowing constituents to meet with elected representatives via video conferencing, METAvivor ensures that the voices of the stage IV community are heard in Washington, D.C., without requiring the grueling physical toll of travel to the capital.
"Our advocacy team is hard at work," Dr. Shanahan stated. "Join us from the comfort of your own home in letting our elected representatives know what is vitally important to their constituents with cancer."
The organization is also launching a community-wide survey. This data-gathering mission is aimed at optimizing their subscriber list and ensuring that the resources provided—whether scientific updates or advocacy toolkits—are meeting the specific needs of a diverse patient population.
Implications: The Human Face of Metastatic Progression
Perhaps the most striking element of the recent announcement is the intersection of professional success and personal health crisis. Dr. Shanahan’s disclosure that her cancer has progressed serves as a stark reminder of the volatility of MBC.
"On a personal note, my cancer has progressed—again—and I am actively seeking a clinical trial," Dr. Shanahan wrote. Her decision to travel from California to Nashville, Tennessee, for a potential trial enrollment illustrates the "trial-chasing" reality many patients face. Her reference to being an "MBC girl"—a play on her interest in the work of Taylor Swift—reflects a culture of resilience and dark humor often found within the metastatic community.
The broader implications of this news are three-fold:
- The Continuity of Patient-Led Research: The fact that a volunteer board, many of whom are facing their own health declines, can manage a $41 million portfolio suggests a highly efficient and motivated organizational model. It challenges the traditional "top-down" approach to medical philanthropy.
- The Clinical Trial Gap: Dr. Shanahan’s need to travel across the country for a trial highlights the urgent need for decentralized clinical trials. If a former physician and president of a major cancer organization must relocate to access care, it raises serious questions about the accessibility of cutting-edge treatments for the average patient.
- The Urgency of the 2025 Grants: Each of the 14 new grants represents more than just scientific inquiry; they represent "time." For the 168,000 Americans currently living with MBC, these research projects are the only hope for turning a terminal diagnosis into a manageable chronic condition.
Conclusion: A Call to Action and Community
As METAvivor prepares to announce the specific awardees of the 2025 grant cycle, the organization remains focused on its dual mission of research and advocacy. The $3.55 million in new funding is a testament to the power of grassroots mobilization, yet the progression of its president’s disease serves as a reminder that the clock is ticking.
The organization’s upcoming survey and the Groundswell event provide immediate avenues for community involvement. For those in the Nashville area or within the global MBC community, Dr. Shanahan’s open invitation to connect at [email protected] underscores the organization’s core value: no one should face the complexities of metastatic disease alone.
In the coming months, the results of the 14 funded studies will be closely watched by the scientific community. For METAvivor, the goal remains unchanged: to fund the research that will one day ensure that metastatic breast cancer is no longer a death sentence, but a disease that people can live with, rather than die from.
About METAvivor:
METAvivor Research and Support is a non-profit organization dedicated to providing support for women and men living with metastatic breast cancer (MBC) and funding research to transition MBC from a terminal illness to a manageable, chronic condition. 100% of all donations go toward MBC research grants.
About the Author
